Dysferlinopathy is a rare, recessively inherited muscular dystrophy caused by mutations in the *DYSF*^[@R1][@R2][@R4]^ gene. Potential therapies are in development, and some of them have entered human clinical trials (NCT02579239, NCT01863004, NCT02710500). As the development of newly licensed and emerging treatments for Duchenne muscular dystrophy^[@R5],[@R6]^ and spinal muscular atrophy type 1^[@R7]^ has shown, proving efficacy and satisfying regulators can be difficult in slowly progressive and varied conditions.^[@R8]^

Appropriate powering of a clinical trial requires understanding of disease progression and responsiveness of various outcome measures over time.^[@R9]^ Selection of outcome measures for clinical trials in dysferlinopathy is particularly challenging. Dysferlinopathy is characterized by a range of ages at onset and patterns of weakness and severity,^[@R4],[@R10]^ variable rate of progression,^[@R4]^ modifying factors that are not clearly elucidated,^[@R10][@R11][@R13]^ and no appropriate measures for monitoring progression. While some measures such as the Motor Function Measure (MFM) have been shown to be reliable in dysferlinopathy,^[@R14]^ the variability of progression makes it difficult to demonstrate responsiveness in small cohorts.

The Jain Clinical Outcome Study in Dysferlinopathy (COS) aims to address these difficulties by characterizing the clinical, biochemical, and radiologic parameters of 209 patients with dysferlinopathy over 3 years.

This article summarizes findings from a planned interim analysis of baseline, 6-month, and year 1 data to determine whether disease progression is detectable and which measures are most able to detect this progress. We propose a power calculation using the most sensitive measures to determine a potential clinical trial cohort required to demonstrate significant functional change.

Methods {#s1}
=======

The COS study {#s1-1}
-------------

The COS study is an international collaborative study of patients with a genetic and/or protein assay--confirmed diagnosis of dysferlinopathy.^[@R4]^ Screening, baseline, 6-month, and 1-year visits took place between October 2012 and March 2016. One hundred ninety-seven of the original 209 recruited patients completed a baseline visit. Of the original 209 patients, 7 did not meet inclusion criteria, and 5 chose not to continue past the screening visit ([figure 1](#F1){ref-type="fig"}). Full inclusion and exclusion criteria, the study protocol, and patient demographics have been described previously.^[@R4]^

![Flowchart of patient numbers at each visit\
Number of patients who completed each assessment (baseline, 6 months, and 12 months) and how many of them were used for each analysis window.](NEUROLOGY2018902411FF1){#F1}

Standard protocol approvals, registrations, and patient consents {#s1-2}
----------------------------------------------------------------

The study was initially approved by the following: NRES Committee North East---Newcastle & North Tyneside on February 2, 2012 (reference 211/NE/0360/R&D 5918). The study was also approved by ethics review boards in each country. All patients provided written informed consent. The trial was registered at [ClinicalTrials.gov](http://ClinicalTrials.gov) (NCT01676077).

Functional outcome measures {#s1-3}
---------------------------

Clinical assessments were standardized through trainings at investigator meetings, and all evaluations were performed by trained clinicians. Assessments included the adapted North Star Ambulatory Assessment (a-NSAA),^[@R4]^ MFM-20, timed function tests (timed rise from floor, 10-m walk/run, 4-stair climb and descend, Timed Up and Go, and the 6-minute walk test \[6MWT\]), Brooke Upper Extremity Scale, Jebsen Hand Function Test, manual muscle testing (MMT), and hand-held dynamometry (HHD). No assessments have been specifically validated in a dysferlin-specific population. These assessments were chosen because of their widespread suitability for limb girdle muscular dystrophy. The MFM-20 was selected over the MFM-32 to reduce patient fatigue and duplication. All assessments were attempted for ambulant patients. Nonambulant patients did not complete the a-NSAA or ambulation-based timed function tests.

Muscle strength was assessed with an 11-point scale for MMT.^[@R4]^ The best of 3 attempts for HHD was used for analysis.

Functional ability was assessed with qualitative scales and timed tests. Total scores were calculated for the a-NSAA^[@R15]^ in ambulant patients, and the MFM-20 and the Brooke scale were calculated in all patients. The MFM-20 was also analyzed on the basis of its 3 components: D1 (standing and transfers), D2 (axial and proximal), and D3 (distal). Any patient with an incomplete score was excluded from analysis for that test. To account for patients who became nonambulant or unable to complete timed function tests due to disease progression, timed test values were converted to velocity measures (either meter per second or task per second), with a 0-m/s velocity assigned for the first instance a patient was unable to complete the test.

Patient perception of progression {#s1-4}
---------------------------------

The ACTIVLIM questionnaire, a Rasch-built patient-reported outcome measure,^[@R16]^ was used to capture patient-reported functional ability. The total score, out of a maximum of 36, was compared between visits. A higher score indicates greater functional ability.

Statistical analysis {#s1-5}
--------------------

Statistical analysis was completed with SAS 9.3 (SAS Institute Inc, Cary, NC). Mean and median change scores were calculated for each test between baseline and 6 months, 6 months and year 1, and baseline and year 1. Data from some visits were excluded if the visit occurred ±2 months outside the scheduled appointment date. A majority of functional outcome measures were not normally distributed; thus, comparisons between baseline and follow-up time points were conducted with the Wilcoxon signed rank-sum test and standardized response mean (SRM).^[@R17]^ A comparison was made between the performance of patients with the most common clinical diagnoses of limb girdle muscular dystrophy 2B (LGMD2B) and Miyoshi myopathy with Kruskal-Wallis test with Steel-Dwass-Critchlow-Fligner correction for multiple comparisons.^[@R18]^

Nonambulant patients (unable to walk 10 meters with usual orthotics and walking aids) were compared to 3 categories of ambulant patients: ambulation affected severely, moderately, or mildly. Using patients' a-NSAA scores at baseline, we defined ambulant severity categories based on a clinical impression of disease severity and binomial distribution of a-NSAA scores, with cut points of 0 to 10 (severe disease severity), 11 to 40 (moderate disease severity), and 41+ (mild disease severity). The lower cut point was based on the end of the first a-NSAA peak, and the high cut point was placed at the start of the second peak, with the wide spread in between representing a plateau between peaks. Significance was defined as *p* ≤ 0.05. Results are expressed as median change (range) and *p* value.

Power analyses to support a hypothetical future clinical trial were conducted to estimate the sample size required to detect significant statistical differences in progression over the course of 1 year with PASS 14 software. Because change scores were normally distributed, calculations used mean change scores and SDs of the functional measure that demonstrated most change over time. For this analysis, the a-NSAA was used, which limited estimates to ambulant patients only. Sample sizes needed to evaluate a variety of expected drug effects were calculated for reference, including halting of disease progression (i.e., assuming mean progression estimates from the current sample among untreated and no progression among treated patients), reflective of potential protein-restoring genetic therapies. An α level of 0.05, 80% power, and a treated-to-untreated ratio of 1:1 were assumed. For comparison with a widely used measure in muscular dystrophy, sample sizes were also calculated on the basis of the 6MWT.

Data availability statement {#s1-6}
---------------------------

Deidentified cohort level data can be requested. All protocol assessments are in the public domain apart from the a-NSAA, which can be requested from the steering group (publication in draft). The statistical plan is detailed above. All data for this natural history study will be stored for at least 5 years after the end of the study. Data can be requested by all interested stakeholders for clinical research and trial planning. Data requests are reviewed by the Jain COS Steering Committee, who can be contacted via the corresponding author.

Results {#s2}
=======

Of the initial 197 eligible enrolled patients, 3 patients withdrew after baseline, and 1 withdrew after 6 months. This is summarized in [figure 1](#F1){ref-type="fig"}. Patients included in this analysis were between 11 and 86 years of age at baseline and were at all stages of disease progression, from asymptomatic hyperCKemia to nonambulant.

Functional outcome measures {#s2-1}
---------------------------

Functional outcome measure results are summarized in [tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, [figure 2](#F2){ref-type="fig"}, and table e-1 (available from Dryad, [doi.org/10.5061/dryad.tp08m60](https://doi.org/10.5061/dryad.tp08m60)). Some of the assessments, by their nature, are suitable only for ambulant patients. In addition, some patients did not complete all assessments because of equipment or individual patient factors such as recent injury and were excluded from analysis of that assessment. The number of patients who completed each assessment is listed.

###### 

Change in scores of functional tests from baseline to 6 months, 6 months to 1 year, and baseline to 1 year for the a-NSAA, MFM, Jebsen, Brooke, patient-reported ACTIVLIM, and 6-minute walk tests

![](NEUROLOGY2018902411TT1)

###### 

Change scores for MMT with a possible range of scores of 0 to 10 and HHM measured with a dynamometer

![](NEUROLOGY2018902411TT2)

![](NEUROLOGY2018902411TT2A)

![Change in timed tests over 6 months and 1 year\
Boxplots showing range, interquartile range (IQR), and median values of time taken to perform timed tests. Paired comparisons of calculated velocity (1/time in seconds) were used to determine significant vs insignificant change in order to include those unable to complete the test. These are displayed as time taken to complete each task (rather than velocity) to aid visual interpretation. Comparisons of baseline and year 1, baseline and 6 months, and 6 months and 1 year are shown. The numbers differ depending on the number of patients completing each test at both visits. Blue shows significant change (*p* \< 0.05) over 1 year; red shows if change is seen over both 6-month periods; and green shows change in only the green 6-month window. Some patients were very slow, and those taking \>25 seconds to complete a test are not displayed but are included in median and IQR calculations.](NEUROLOGY2018902411FF2){#F2}

The a-NSAA, MFM-20 (total and subdomain D1), the Timed Up and Go, and timed 10-meter walk showed significant change in median score over both 6-month periods and 1 year ([table 1](#T1){ref-type="table"} and [figure 2](#F2){ref-type="fig"}); no MMT or HHD values changed consistently over both 6-month windows ([table 2](#T2){ref-type="table"}).

The MFM D2, some MMT and HHD, velocity to rise from floor, climb 4 stairs, descend 4 stairs, and the 6MWT showed significant change over only one 6-month window and over 1 year ([tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} and [figure 2](#F2){ref-type="fig"}).

The MFM D3, some MMT and HHD, and the Brooke scale showed change in median score at 1 year but did not change over either 6-month windows ([tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

The timed test demonstrating the greatest change in velocity was the 10-meter walk, changing −0.1 m/s (range −1.24 to 0.55 m/s) from a baseline median velocity of 1.11 m/s (range 0.00--4.55 m/s). The velocity of all timed tests at year 1 slowed by almost 10% of baseline velocity for that task ([figure 2](#F2){ref-type="fig"}).

The Jebsen Hand Function Test and remaining MMT and HHD tests showed no change over 1 year.

The tests most responsive to change for the whole cohort, as calculated by the SRM, were NSAA (SRM 0.61), 10-meter walk/run velocity (0.56), ACTIVLIM (0.46), rise from floor velocity (0.44), and MFM total score (0.44).

When assessed by severity subgroup, for ambulant patients, the a-NSAA was the most sensitive test in the mildly (SRM 0.44) and moderately (SRM 0.89) affected groups, while the 6MWT was most sensitive in the severely affected ambulant group (SRM 0.9). The 10-meter walk was the only test showing significant change in all ambulant subgroups. For nonambulant patients, the most sensitive test was the MMT for wrist flexion (SRM 0.69), while the most sensitive combined measure was the distal domain of the MFM (SRM 0.46). Table e-1 (available from Dryad [doi.org/10.5061/dryad.tp08m60](https://doi.org/10.5061/dryad.tp08m60)) shows SRM values for all assessments by severity subgroup. Change in functional test scores (MFM and a-NSAA) did not differ between the 2 most common clinical diagnoses of LGMD2B and Miyoshi myopathy ([table 3](#T3){ref-type="table"}).

###### 

Scores in LGMD2B and Miyoshi myopathy

![](NEUROLOGY2018902411TT3)

![](NEUROLOGY2018902411TT3A)

Patient perception of progression {#s2-2}
---------------------------------

Responses recorded by the ACTIVLIM questionnaire supported the deterioration in function, with the ACTIVLIM score decreasing statistically significantly over both 6 and 12 months ([table 1](#T1){ref-type="table"}).

Estimated sample size for trials {#s2-3}
--------------------------------

Estimated clinical trial sample size is highly dependent on the expected treatment effect; the smaller the effect size, the larger the sample required ([table 4](#T4){ref-type="table"}). For example, with the inclusion of ambulant patients of all disease severities, a total of 328 patients (164 in both the treatment and placebo groups) would be needed to detect a 50% reduction in disease progression (i.e., half the deterioration seen in the current sample) over 1 year compared to 90 patients (45 in each group) needed to detect halting in progression. The a-NSAA was chosen for its capability to detect change as demonstrated by the highest overall SRM in the current analysis. Limiting a clinical trial to a subset of patients in the moderate severity group at baseline, who showed the greatest changes in a-NSAA scores over 1 year, would reduce the total sample size to 176 for a 50% reduction in progression and 46 to detect a halt in progression. A treatment that is anticipated to improve muscle function, producing a greater effect size than simply halting progression, would require even fewer patients.

###### 

Sample size estimates for a placebo-controlled clinical trial

![](NEUROLOGY2018902411TT4)

The 6MWT would require 216 ambulant patients to detect a halting of progression. However, as reflected by the high SRM in the severe-ambulant population, if trials were limited to the severe-ambulant subgroup of patients, 42 patients would be needed to detect a halting in progression with the 6MWT.

Discussion {#s3}
==========

This analysis supports the use of specified physical and patient-reported outcome measures in the assessment of dysferlinopathy by demonstrating clinically detectable deterioration in muscle strength and function and self-reported deterioration over 6 months and 1 year in a large cohort of patients.

Defining a set of disease specific tests is useful in coordinating further research and patient follow-up and developing clinical trial outcome measures. The most sensitive assessments for monitoring progression in dysferlinopathy that were identified in this study are the a-NSAA, MFM-20, timed 10-meter walk, and Timed Up and Go; they demonstrated consistent change over both 6 months and 1 year with a relatively high SRM. Other tests such as the Brooke and some MMT assessments showed change over 1 year but not 6 months, suggesting that they are less sensitive scales. This was also true for D3 (distal function) of the MFM, consistent with other published cross-sectional data on its poor suitability for this population.^[@R14]^ Some tests such as the 6MWT and MFM D2 domain changed over one 6-month window but not the other. This poor repeatability of demonstrable change makes these measures less reliable in assessing the dysferlinopathy patient cohort as a whole.

The 6MWT showed the highest SRM for the severely affected ambulant patients, perhaps capturing a large deterioration in the walking pace of some of these weak patients as they lose ambulation. However, this is unlikely to be used in clinical trials, particularly because this subgroup of patients is small (37 severe-ambulant patients in this study), thus reducing the number of patients available to appropriately power a study.

Trials in rare diseases are often forced to rely on small cohort sizes. Here, we show that while variation in physical progression can be high in dysferlinopathy, sensitive outcome measures can be identified (a-NSAA, 10-meter walk, etc.), particularly in ambulant patients. We confirm that a moderate disease severity group based on the a-NSAA could be identified, making it possible to power a clinical trial with a reasonably sized sample. The actual number needed would depend on the expected treatment effect over 1 year. Numbers needed for a trial could be further reduced by using this longitudinal natural history sample as a control group for future clinical studies.^[@R19]^ In addition, longer evaluation times and identification of more sensitive scoring systems could further reduce the number of participants needed for effective clinical trials. Future work aiming to assess the cohort by modeling methods will look at progression based on a variety of disease and environmental factors to attempt to determine whether any subgroups exist with differing rates of progression. Any particularly fast-progressing group would be very good candidates for potential trials in terms of both patient benefit and reduced sample size requirement.

Increasing the sensitivity and utility of functional scoring systems across the disease spectrum requires the creation of a disease-specific scale. We are working to streamline the a-NSAA and MFM-20 to remove redundant and less sensitive items and to combine elements of each scale using a Rasch analysis^[@R20]^ to create a linearizable, dysferlin-specific score. This modified scale, called the North Star Assessment for Dysferlinopathy, will be validated with the 2- and 3-year COS visits and will be assessed with Rasch analysis to determine whether the new scale is capable of measuring change over a wider proportion of the patient population over time.

Characterizing which individual muscles demonstrate most rapid deterioration in dysferlinopathy is useful for both monitoring progression and targeting potential therapeutics, some of which involve local intramuscular injections.^[@R21]^ These results over 1 year show some sensitivity to change of a few distal muscle groups in nonambulant patients, in whom functional scores are less useful. However, in ambulant patients, there is a low responsiveness and high variability of MMT and HHD results because measures of specific muscle change. Other measures of strength, longer time scales, and MRI may be needed to monitor effects of local treatments.

In all tests, a small number of individuals of all ages and disease severities improved their time or qualitative functional score over 1 year. While in some this may reflect a true improvement in function, we would not expect an improvement in underlying pathology. Therefore, it is likely that some of this improvement can be attributed to potentially confounding factors. With functional scales, improvement may be due to a learning effect^[@R22]^; that is, patients become more practiced at certain tests, although we attempted to mitigate this by having all patients perform a full assessment at screening. Some intertester variation in scoring is also possible because, although all were trained by the same provider, different physiotherapists conducted consecutive patient visits at some sites. However, we anticipate this effect to be small because the functional assessments used have previously demonstrated high intertester reliability in other diseases,^[@R23][@R24][@R25]^ and intraclass correlation comparison of baseline and screening results ([table 5](#T5){ref-type="table"}) shows consistency of scoring, particularly for the a-NSAA (intraclass correlation 0.99), on which much of this analysis is based. Finally, this may simply reflect environmental, physiologic, or individual factors such as motivation or fatigue, which can cause natural fluctuations in performance on functional tests^[@R22]^ on the background of more slowly progressing pathology. If trends in scores are maintained in future visits, suggesting a true subgroup of static or even functionally improving patients, this will be revisited to assess for potential disease modifiers.

###### 

Intraclass correlation coefficient between screening and baseline assessments for functional tests carried out at a maximum of 90 days apart

![](NEUROLOGY2018902411TT5)

The ACTIVLIM is a rating scale with documented high sensitivity in many neuromuscular conditions.^[@R16],[@R26]^ We have shown that this holds true for the dysferlinopathy population, who show changes in score across all levels of function. A very small number of patients reported an improvement in the ability to perform tasks of daily living. These patients had undertaken lifestyle changes, including weight loss, dietary change, and participation in physiotherapy. Future work will explore and capture patient access to physiotherapy, participation in exercise, and the use of aids and adaptations in the home and workplace. These findings suggest that the ACTIVLIM is a reliable patient-reported outcome measure in dysferlinopathy that is a valuable complementary tool for clinical trials at any stage of the disease.

There are several limitations of this study. The first is the relatively short period of time over which change was examined; this will be addressed in future analysis of this 3-year study. Second, the use of ordinal, rather than continuous, functional scales presented challenges in data analysis, necessitating the use of medians, making intuitive interpretation more difficult. However, these scales also have benefits because a single point change on a functional change necessarily represents a clinically, rather than simply statistically, noticeable change. Future work will explore the potential to linearize these Rasch-based measures, allowing us to keep the benefits of these scales while providing the opportunity to subject them to more rigorous parametric statistics.

Although function is measured, the importance attributed by patients to the loss of ability to perform 1 particular action over another is not measured here. To clarify the clinical significance of the statistically significant changes demonstrated here, further correlations are needed between these functional and patient-reported measures, as well as consideration of patient valuation of the importance of the loss of individual functions.

Our current assessment of arm function is limited in the scales currently used in this study. Further work is required to develop or determine suitable measures for upper limb function.

This study demonstrates significant population-level change over 6 months and 1 year in several functional and patient-reported measures. We anticipate that the planned combination of the most sensitive elements of the a-NSAA and MFM to create a dysferlin-specific score will produce an important measure that will become the basis for assessment of progression in dysferlinopathy regardless of ambulatory status. This measure combined with MRI data and further patient subgroup analysis will add to the pathophysiologic understanding and trial readiness of the dysferlinopathy population and may further reduce the cohort size required to power potential clinical trials.

This study has been possible only thanks to the international collaboration of several specialized centers promoted by the Jain Foundation. The Jain COS Consortium thanks the study participants and their families for their invaluable contributions and acknowledges the ongoing support that the Jain Foundation provides in the development, management, and analysis of this study. The Jain Foundation, based in Seattle, WA, is focused entirely on LGMD2B/dysferlinopathy/Miyoshi myopathy. The foundation does not solicit funding from patients but instead funds research and clinical studies worldwide with the goal of finding treatments for dysferlinopathy. Please visit [jain-foundation.org](http://www.jain-foundation.org/) for more information about the foundation. If you are a patient with dysferlinopathy, please consider enrolling in their interactive dysferlinopathy registry, which seeks to build a strong, engaged, and supportive community (<patients@jain-foundation.org>).
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a-NSAA

:   adapted North Star Ambulatory Assessment

COS

:   Jain Clinical Outcome Study in Dysferlinopathy

HHD

:   hand-held dynamometry

LGMD2B

:   limb girdle muscular dystrophy 2B

MFM

:   Motor Function Measure

MMT

:   manual muscle testing

6MWT

:   6-minute walk test

SRM

:   standardized response mean
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